Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Neal II, Robert E ^a,b   Rossmeisl, John H ^b   Robertson, John L ^b   Arena, Christopher B ^b   Davis, Erica M ^b   Singh, Ravi N ^c   Stallings, Jonathan ^b   Davalos, Rafael V ^b  

^a ALFRED HOSPITAL   (Australia)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IRREVERSIBLE ELECTROPORATION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; STRAIN DIFFERENCE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR LOCALIZATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; ELECTROPORATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MORTALITY; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; IMMUNOCOMPROMISED HOST; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; TUMOR BURDEN;

EID: 84878147451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064559     Document Type: Article

References (52)

1. Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, et al. (2001) Radiofrequency ablation of solid tumors. Cancer J 7: 95-102.
2. Skinner MG, Iizuka MN, Kolios MC, Sherar MD, (1998) A theoretical comparison of energy sources- microwave, ultrasound and laser- for interstitial thermal therapy. Physics in Medicine and Biology 43: 3535-3547.
3. Sabel MS, Kaufman CS, Whitworth P, Change H, Stocks LH, et al. (2004) Cryoablation of Early-Stage Breast Cancer: Work-in-Progress Report of a Multi-Institutional Trial. Ann Surg Oncol 11: 542-549.
4. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, et al. (2008) Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34: 232-240.
5. Neal RE 2nd, Rossmeisl JH Jr, Garcia PA, Lanz OI, Henao-Guerrero N, et al (2011) Successful Treatment of a Large Soft Tissue Sarcoma With Irreversible Electroporation. J Clin Oncol 29: e372-377.
6. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, et al. (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22: 611-621.
7. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, et al. (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59: 5059-5063.
8. Onik G, Mikus P, Rubinsky B, (2007) Irreversible Electroporation: Implications for Prostate Ablation. Technol Cancer Res Treat 6: 295-300.
9. Maor E, Ivorra A, Leor J, Rubinsky B, (2007) The Effect of Irreversible Electroporation on Blood Vessels. Technol Cancer Res Treat 6: 307-312.
10. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B, (2006) In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation. IEEE Trans Biomed Eng 53: 1409-1415.
11. Miklavcic D, Semrov D, Mekid H, Mir LM, (2000) A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta 1523: 73-83.
12. Lee EW, Loh CT, Kee ST, (2007) Imaging Guided Percutaneous Irreversible Electroporation: Ultrasound and Immunohistological Correlation. Technol Cancer Res Treat 6: 287-293.
13. Rubinsky B, Onik G, Mikus P, (2007) Irreversible Electroporation: A New Ablation Modality- Clinical Implications. Technol Cancer Res Treat 6: 37-48.
14. Neal RE 2nd, Singh R, Hatcher HC, Kock ND, Torti SV, et al (2010) Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode. Breast Cancer Res Treat 123: 295-301.
15. Al-Sakere B, Andre F, Bernat C, Connault E, Opolon P, et al. (2007) Tumor Ablation with Irreversible Electroporation. PLoS One 2: e1135.
16. Garcia PA, Pancotto T, Rossmeisl JH Jr, Henao-Guerrero N, Gustafson NR, et al. (2011) Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol Cancer Res Treat 10: 73-83.
17. Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, et al. (2012) Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 23: 1613-1621.
18. Martin RCG, McFarland K, Ellis S, Velanovich V, (2012) Irreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic Adenocarcinoma. J Am Coll Surgeons 215: 361-369.
19. Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, et al. (2011) Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer 128: 2653-2662.
20. Sabel MS, (2009) Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58: 1-11.
21. Gravante G, Sconocchia G, Ong SL, Dennison AR, Lloyd DM, (2009) Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 29: 18-24.
22. Soanes WA, Ablin RJ, Gonder MJ, (1970) Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol 104: 154-159.
23. Tanaka S, (1982) Immunological aspects of cryosurgery in general surgery. Cryobiology 19: 247-262.
24. Saito K, Araki K, Reddy N, Guang W, O'Malley BW Jr, et al. (2011) Enhanced local dendritic cell activity and tumor-specific immunoresponse in combined radiofrequency ablation and interleukin-2 for the treatment of human head and neck cancer in a murine orthotopic model. Head Neck 33: 359-367.
25. Thakur A, Littrup P, Paul EN, Adam B, Heilbrun LK, et al. (2011) Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother 34: 457-467.
26. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, et al. (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57: 1291-1300.
27. Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D, et al. (1995) Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol 17: 30-38.
28. Yamashita YI, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, et al. (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61: 1005-1012.
29. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, et al. (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
30. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R, (2000) In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10: 577-583.
31. Li X, Xu K, Li W, Qiu X, Ma B, et al. (2012) Immunologic Response to Tumor Ablation with Irreversible Electroporation. PLoS ONE 7: e48749.
32. Salup RR, Herberman RB, Wiltrout RH, (1985) Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol 134: 1236-1241.
33. Al-Sakere B, Bernat C, Andre F, Connault E, Opolon P, et al. (2007) A Study of the Immunological Response to Tumor Ablation with Irreversible Electroporation. Technol Cancer ResTreat 6: 301-305.
34. Fuchs EJ, Matzinger P, (1996) Is cancer dangerous to the immune system? Semin Immunol 8: 271-280.
35. Matzinger P, (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
36. Valenzuela J, Schmidt C, Mescher M, (2002) The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 169: 6842-6849.
37. Curtsinger JM, Lins DC, Mescher MF, (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197: 1141-1151.
38. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, et al. (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434.
39. Gallucci S, Lolkema M, Matzinger P, (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5: 1249-1255.
40. Skoberne M, Beignon AS, Bhardwaj N, (2004) Danger signals: a time and space continuum. Trends Mol Med 10: 251-257.
41. Peng Y, Martin DA, Kenkel J, Zhang K, Ogden CA, et al. (2007) Innate and adaptive immune response to apoptotic cells. J Autoimmun 29: 303-309.
42. Viorritto IC, Nikolov NP, Siegel RM, (2007) Autoimmunity versus tolerance: can dying cells tip the balance? Clin Immunol 122: 125-134.
43. Scheinecker C, McHugh R, Shevach EM, Germain RN, (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 196: 1079-1090.
44. Huang FP, Platt N, Wykes M, Major JR, Powell TJ, et al. (2000) A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 191: 435-444.
45. Mir LM, Orlowski S, (1999) Mechanisms of electrochemotherapy. Adv Drug Deliv Rev 35: 107-118.
46. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, et al. (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13: 449-459.
47. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, et al. (2010) Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 255: 426-433.
48. Zhou W, Xiong Z, Liu Y, Yao C, Li C, (2012) Low voltage irreversible electroporation induced apoptosis in HeLa cells. J Cancer Res Ther 8: 80-85.
49. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, et al. (1999) Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 59: 3329-3332.
50. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, et al. (2003) Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 103: 205-211.
51. Nuccitelli R, Tran K, Lui K, Huynh J, Athos B, et al. (2012) Non-thermal nanoelectroablation of UV-induced murine melanomas stimulates an immune response. Pigment Cell Melanoma Res 25: 618-629.
52. Miyazaki S, Gunji Y, Matsubara H, Shimada H, Uesato M, et al. (2003) Possible involvement of antitumor immunity in the eradication of colon 26 induced by low-voltage electrochemotherapy with bleomycin. Surg Today 33: 39-44.